Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Long-Term Investments (2016 - 2025)

Cytokinetics (CYTK) has disclosed Long-Term Investments for 14 consecutive years, with $335.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Investments changed N/A to $335.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $335.0 million, a N/A change, with the full-year FY2025 number at $335.0 million, changed N/A from a year prior.
  • Long-Term Investments was $335.0 million for Q4 2025 at Cytokinetics, up from $288.8 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $335.0 million in Q4 2025 to a low of $10.7 million in Q2 2022.
  • A 5-year average of $120.0 million and a median of $73.7 million in 2021 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: tumbled 85.52% in 2022, then skyrocketed 1640.16% in 2024.
  • Cytokinetics' Long-Term Investments stood at $152.0 million in 2021, then tumbled by 69.28% to $46.7 million in 2022, then fell by 13.22% to $40.5 million in 2023, then soared by 564.05% to $269.2 million in 2024, then increased by 24.48% to $335.0 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Long-Term Investments are $335.0 million (Q4 2025), $288.8 million (Q3 2025), and $178.2 million (Q2 2025).